Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06852469 · ClinicalTrials.gov registry record · Phase 4
Computational Assessment of GABA Receptor Modulation in PTSD
A Phase 4 study of Stress Disorders, Post-Traumatic, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06852469 is a Phase 4 study of Stress Disorders, Post-Traumatic that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 150 participants, roughly in line with the 153-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06852469, a Phase 4 study of Stress Disorders, Post-Traumatic, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
A substantial majority of Veterans with posttraumatic stress disorder (PTSD) continue to suffer even with the best current medications. Progress in developing more effective medications is hampered by the substantial variability within Veterans with PTSD, meaning the most effective medication likely varies from individual to individual. New scientific tools to help identify distinct subgroups of Veterans with PTSD who are likely to respond to specific medications could help improve treatment in this population. Research has indicated that a specific subgroup of Veterans with PTSD with a high level of anxious arousal may benefit from medications which boost signaling of the neurotransmitter gamma-aminobutyric acid (GABA). This project aims to validate a clinical test to identify these individuals using new computational and neuroimaging methods combined with the medication lorazepam, a positive GABA modulator. The ultimate goal is to use these methods in future clinical trials of new medications to target the best treatments to individual Veterans with PTSD.
Conditions Studied
Interventions
- DRUG Placebo tablet
- DRUG Lorazepam 1 mg tablet
Study Locations (1)
California
- VA San Diego Healthcare System, San Diego, CA - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06852469
The ClinicalTrials.gov registry entry for NCT06852469 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 153-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo tablet is the first listed.
NCT06852469 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06852469 about?
NCT06852469 is a clinical study titled "Computational Assessment of GABA Receptor Modulation in PTSD". A substantial majority of Veterans with posttraumatic stress disorder (PTSD) continue to suffer even with the best current medications. Progress in developing more effective medications is hampered by the substantial variability within Veterans with PTSD, meaning the most effective medication likely...
What is the current status of trial NCT06852469?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2025-07-01. Estimated completion is 2029-06-30.
What conditions does trial NCT06852469 study?
This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic.
What interventions are being tested in trial NCT06852469?
The interventions under investigation include: Placebo tablet (DRUG), Lorazepam 1 mg tablet (DRUG).
Who is sponsoring clinical trial NCT06852469?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06852469 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Disorders, Post-Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery
RECRUITING · Phase 4
-
CPT-SMART for Treatment of PTSD and Cigarette Smoking
COMPLETED · Phase 4
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
SMART Therapist Training: A Hybrid Factorial-SMART Design
RECRUITING · NA
-
Overcontrol and Suicide in PTSD
RECRUITING
-
Postpartum Care in the NICU (PeliCaN) Transitions
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.